Veru (VERU) 10-Q 13 Feb 25 2025 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Dec. 31, 2024	Feb. 10, 2025
Document Information [Line Items]
Entity Central Index Key	0000863894
Entity Registrant Name	VERU INC.
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2025
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Dec. 31, 2024
Document Transition Report	false
Entity File Number	1-13602
Entity Incorporation, State or Country Code	WI
Entity Tax Identification Number	39-1144397
Entity Address, Address Line One	2916 N. Miami Avenue, Suite 1000
Entity Address, City or Town	Miami
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33127
City Area Code	305
Local Phone Number	509-6897
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	VERU
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		146,383,920

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2024	Sep. 30, 2024
Assets
Cash, cash equivalents, and restricted cash	$ 26,607,002	$ 24,916,285
Prepaid expenses and other current assets	1,773,134	1,547,928
Current assets of discontinued operations	0	8,759,011
Total current assets	28,380,136	35,223,224
Property and equipment, net	452,043	481,372
Operating lease right-of-use assets	3,127,887	3,250,623
Goodwill	6,878,932	6,878,932
Other assets	989,596	989,596
Long-term assets of discontinued operations	0	13,595,025
Total assets	39,828,594	60,418,772
Liabilities and Stockholders' Equity
Accounts payable	1,994,645	2,259,668
Accrued research and development costs	1,572,429	120,448
Accrued compensation	1,503,233	4,494,278
Accrued expenses and other current liabilities	535,472	549,237
Residual royalty agreement liability, short-term portion	0	1,025,837
Operating lease liability, short-term portion	742,449	736,970
Current liabilities of discontinued operations	0	2,681,530
Total current liabilities	6,348,228	11,867,968
Residual royalty agreement liability, long-term portion	0	8,850,792
Operating lease liability, long-term portion	2,775,190	2,905,309
Other liabilities	4,078,187	4,461,920
Long-term liabilities of discontinued operations	0	16,071
Total liabilities	13,201,605	28,102,060
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock; no shares issued and outstanding at December 31, 2024 and September 30, 2024	0	0
Common stock, par value $0.01 per share; 308,000,000 shares authorized, 148,567,624 issued and 146,383,920 shares outstanding at December 31, 2024 and September 30, 2024	1,485,676	1,485,676
Additional paid-in-capital	336,462,900	333,788,795
Accumulated other comprehensive loss	0	(581,519)
Accumulated deficit	(303,514,982)	(294,569,635)
Treasury stock, 2,183,704 shares, at cost	(7,806,605)	(7,806,605)
Total stockholders' equity	26,626,989	32,316,712
Total liabilities and stockholders' equity	$ 39,828,594	$ 60,418,772

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2024	Sep. 30, 2024
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	308,000,000	308,000,000
Common stock, issued (in shares)	148,567,624	148,567,624
Common stock, outstanding (in shares)	146,383,920	146,383,920
Treasury stock, at cost (in shares)	2,183,704	2,183,704

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating expenses:
Research and development	$ 5,716,830	$ 1,658,574
Selling, general and administrative	5,227,113	6,651,624
Total operating expenses	10,943,943	8,310,198
Gain on sale of ENTADFI® assets	695,216	918,372
Operating loss from continuing operations	(10,248,727)	(7,391,826)
Non-operating income (expenses):
Gain on extinguishment of debt	8,624,778	0
Change in fair value of equity securities	(349,078)	(379,898)
Other income, net	163,124	104,341
Total non-operating income (expenses)	8,438,824	(275,557)
Net loss from continuing operations	(1,809,903)	(7,667,383)
Net loss from discontinued operations, net of taxes	(7,135,444)	(608,598)
Net income (loss)	$ (8,945,347)	$ (8,275,981)
Net loss from continuing operations per basic and diluted common shares outstanding (in dollars per share)	$ (0.01)	$ (0.08)
Net loss from discontinued operations per basic and diluted common shares outstanding (in dollars per share)	(0.05)	(0.01)
Net loss per basic and diluted common shares outstanding (in dollars per share)	$ (0.06)	$ (0.08)
Basic and diluted weighted average common shares outstanding (in shares)	146,383,920	100,601,946

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Jefferies Sales Agreement [Member] Common Stock [Member]	Jefferies Sales Agreement [Member] Additional Paid-in Capital [Member]	Jefferies Sales Agreement [Member] AOCI Attributable to Parent [Member]	Jefferies Sales Agreement [Member] Retained Earnings [Member]	Jefferies Sales Agreement [Member] Treasury Stock, Common [Member]	Jefferies Sales Agreement [Member]	Lincoln Park Purchase Agreement [Member] Common Stock [Member]	Lincoln Park Purchase Agreement [Member] Additional Paid-in Capital [Member]	Lincoln Park Purchase Agreement [Member] AOCI Attributable to Parent [Member]	Lincoln Park Purchase Agreement [Member] Retained Earnings [Member]	Lincoln Park Purchase Agreement [Member] Treasury Stock, Common [Member]	Lincoln Park Purchase Agreement [Member]	Public Offering [Member] Common Stock [Member]	Public Offering [Member] Additional Paid-in Capital [Member]	Public Offering [Member] AOCI Attributable to Parent [Member]	Public Offering [Member] Retained Earnings [Member]	Public Offering [Member] Treasury Stock, Common [Member]	Public Offering [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Total
Balance (in shares) at Sep. 30, 2023																			93,966,402
Balance at Sep. 30, 2023																			$ 939,664	$ 283,894,830	$ (581,519)	$ (256,768,209)	$ (7,806,605)	$ 19,678,161
Share-based compensation																			0	3,406,949	0	0	0	3,406,949
Net Income (loss)																			$ 0	0	0	(8,275,981)	0	(8,275,981)
Balance (in shares) at Dec. 31, 2023																			148,564,890
Balance at Dec. 31, 2023																			$ 1,485,649	323,548,937	(581,519)	(265,044,190)	(7,806,605)	51,602,272
Issuance of shares (in shares)	90,156						1,800,000					1,800,000	52,708,332
Issuance of shares	$ 902	$ 65,649	$ 0	$ 0	$ 0	$ 66,551	$ 18,000	$ 1,643,490	$ 0	$ 0	$ 0	$ 1,661,490	$ 527,083	$ 34,702,332	$ 0	$ 0	$ 0	$ 35,229,415
Amortization of deferred costs												$ (164,000)								(164,313)				(164,313)
Balance (in shares) at Sep. 30, 2024																			148,567,624
Balance at Sep. 30, 2024																			$ 1,485,676	333,788,795	(581,519)	(294,569,635)	(7,806,605)	32,316,712
Share-based compensation																			0	2,674,105	0	0	0	2,674,105
Release of cumulative foreign currency translation adjustment to discontinued operations																			0	0	581,519	0	0	581,519
Net Income (loss)																			$ 0	0	0	(8,945,347)	0	(8,945,347)
Balance (in shares) at Dec. 31, 2024																			148,567,624
Balance at Dec. 31, 2024																			$ 1,485,676	$ 336,462,900	$ 0	$ (303,514,982)	$ (7,806,605)	$ 26,626,989
Issuance of shares (in shares)						90,156						0
Issuance of shares						$ 67,000

Unaudited Condensed Consolida_5

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
OPERATING ACTIVITIES
Net income	$ (8,945,347)	$ (8,275,981)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	64,870	72,129
Noncash change in right-of-use assets	199,580	198,747
Noncash interest expense, net of interest paid	(168,556)	(28,147)
Gain on extinguishment of debt	(8,624,778)	0
Loss on sale of FC2 business	4,204,435	0
Gain on sale of ENTADFI® assets	(695,216)	(918,372)
Share-based compensation	2,674,105	3,406,949
Deferred income taxes	(1,915)	(81,286)
Change in fair value of derivative liabilities	3,138,316	2,000
Change in fair value of equity securities	349,078	379,898
Other	(72,831)	12,958
Changes in current assets and liabilities:
(Increase) decrease in accounts receivable	(657,253)	2,123,571
Decrease (increase) in inventories	863,928	(201,814)
Increase in prepaid expenses and other assets	(511,038)	(1,340,373)
Decrease in accounts payable	(1,282,454)	(2,495,250)
(Decrease) increase in accrued expenses and other liabilities	(1,643,235)	1,295,516
Decrease in operating lease liabilities	(224,676)	(170,934)
Net cash used in operating activities	(11,332,987)	(6,020,389)
INVESTING ACTIVITIES
Proceeds from sale of FC2 business, net of costs	16,157,965	0
Cash proceeds from sale of ENTADFI® assets	695,216	0
Proceeds from sale of equity securities	393,217	0
Capital expenditures	(1,083)	0
Net cash provided by investing activities	17,245,315	0
FINANCING ACTIVITIES
Payment on extinguishment of residual royalty agreement liabilities	(4,221,611)	0
Installment payments on premium finance agreement	0	(132,975)
Net cash (used in) provided by financing activities	(4,221,611)	36,973,954
Net increase in cash, cash equivalents, and restricted cash	1,690,717	30,953,565
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT BEGINNING OF PERIOD	24,916,285	9,625,494
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF PERIOD	26,607,002	40,579,059
Supplemental disclosure of cash flow information:
Cash paid for interest	332,826	193,104
Schedule of non-cash investing and financing activities:
Equity securities received for sale of ENTADFI® assets	0	918,372
Amortization of deferred costs related to common stock purchase agreement	0	164,313
Costs related to public offering in accounts payable or accrued expenses and other current liabilities	0	149,473
Lincoln Park Purchase Agreement [Member]
FINANCING ACTIVITIES
Proceeds from sale of shares	0	1,661,490
Public Offering [Member]
FINANCING ACTIVITIES
Proceeds from sale of shares	0	35,378,888
Jefferies Sales Agreement [Member]
FINANCING ACTIVITIES
Proceeds from sale of shares	$ 0	$ 66,551

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	Note 1 Basis of Presentation and Significant Accounting Policies The accompanying unaudited interim condensed consolidated financial statements for Veru Inc. (“we,” “our,” “us,” “Veru” or the “Company”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting of interim financial information. Pursuant to these rules and regulations, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) have been condensed or omitted, although the Company believes that the disclosures made are adequate to make the information not not 10 September 30, 2024 September 30, 2024 three December 31, 2024 not September 30, 2025 The preparation of our unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments (consisting of only normally recurring adjustments) necessary to present fairly the financial position and results of operations as of the dates and for the periods presented. Principles of consolidation and nature of operations December 30, 2024, FC2 3 December 30, 2024. December 31, 2024 not FC2 Condom/FC2 FC2 FC2 December 30, 2024. 3 December 2021. April 19, 2023. 15 three December 31, 2024 2023 FC2 Reclassifications no Other comprehensive loss three December 31, 2024 2023 Recent accounting pronouncements not November 2023, 2023 07, 280 2023 07 September 30, 2025, In December 2023, 2023 09, 740 2023 09 September 30, 2026, In November 2024, 2024 03, 220 40 January 2025, 2025 01 2024 03. 2024 03 September 30, 2028, 2024 03 We have reviewed all other recently issued accounting pronouncements and have determined that such standards that are not not not

Note 2 - Going Concern

Note 2 - Going Concern	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 2 Going Concern The Company is not twelve may not These uncertainties raise substantial doubt regarding our ability to continue as a going concern for a period of twelve not 205 40, twelve

Note 3 - Discontinued Operation

Note 3 - Discontinued Operations	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	Note 3 Discontinued Operations On December 30, 2024, “FC2 FC2 FC2 December 30, 2024. The purchase price for the FC2 90 FC2 8 FC2 FC2 FC2 December 30, 2024 In connection with the FC2 six 12 six six Pursuant to the terms of the Purchase Agreement, the Company, the Purchaser, and an escrow agent entered into an Escrow Agreement at closing, pursuant to which the Purchaser deposited $0.4 million of the aggregate purchase price of the FC2 1 may 2 not December 31, 2024 The FC2 FC2 not September 30, 2024. FC2 FC2 December 31, 2024 The following table presents results of discontinued operations for the three December 31, 2024 2023 Three Months Ended December 31, 2024 2023 Net revenues $ 4,484,591 $ 2,140,726 Cost of sales 2,900,514 990,274 Gross profit 1,584,077 1,150,452 Operating expenses: Selling, general and administrative 1,101,987 1,641,283 Total operating expenses 1,101,987 1,641,283 Loss on sale of FC2 business (4,204,435 ) — Operating loss (3,722,345 ) (490,831 ) Non-operating expenses: Interest expense (164,270 ) (164,957 ) Change in fair value of derivative liabilities (3,138,316 ) (2,000 ) Other expense, net (31,960 ) (23,249 ) Total non-operating expenses (3,334,546 ) (190,206 ) Loss before income taxes (7,056,891 ) (681,037 ) Income tax expense (benefit) 78,553 (72,439 ) Net loss from discontinued operations, net of taxes $ (7,135,444 ) $ (608,598 ) The following table presents the carrying amounts of assets and liabilities of discontinued operations as of September 30, 2024: September 30, 2024 Current assets: Accounts receivable, net $ 3,960,305 Inventories, net 4,144,179 Prepaid expenses and other current assets 654,527 Total current assets of discontinued operations $ 8,759,011 Long-term assets: Plant and equipment, net $ 803,282 Operating lease right-of-use asset 311,150 Deferred income taxes 12,340,237 Other assets 140,356 Total long-term assets of discontinued operations $ 13,595,025 Current liabilities: Accounts payable $ 777,173 Accrued compensation 185,418 Accrued expenses and other current liabilities 1,390,412 Operating lease liability, short-term portion 328,527 Total current liabilities of discontinued operations $ 2,681,530 Long-term liabilities: Operating lease liability, long-term portion $ 16,071 Long-term liabilities of discontinued operations $ 16,071 The cash flows related to discontinued operations have not FC2, three December 31, 2024 2023 Three Months Ended December 31, 2024 2023 Total net cash (used in) provided by operating activities from discontinued operations $ (325,454 ) $ 1,525,846 Total net cash provided by investing activities from discontinued operations $ 16,156,882 $ —

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 4 Fair Value Measurements ASC 820 1 3 The three Level 1 Level 2 not Level 3 As September 30, 2024 3 three December 31, 2024 8 The following table provides a reconciliation of the beginning and ending liability balance associated with embedded derivatives measured at fair value using significant unobservable inputs (Level 3 December 31, 2024 2023 Three Months Ended December 31, 2024 2023 Beginning balance $ 1,570,000 $ 1,331,000 Change in fair value of derivative liabilities 3,138,316 2,000 Extinguishments (4,708,316 ) — Ending balance $ — $ 1,333,000 The gain or loss associated with the change in fair value of the embedded derivatives is included within net loss from discontinued operations on the accompanying unaudited condensed consolidated statements of operations. It is included in discontinued operations because the related debt was required to be repaid as a result of the FC2 There is no FC2 FC2 December 30, 2024, FC2 The following tables present quantitative information about the inputs and valuation methodologies used to determine the fair value of the embedded derivatives classified in Level 3 December 30, 2024, September 30, 2024 Valuation Methodology Significant Unobservable Input December 30, 2024 September 30, 2024 Scenario-Based Estimated change of control dates December 2024 March 2025 to March 2027 Discount rate N/A 12.1% to 12.3% Probability of change of control 100 % 60% to 90% The Company also had an investment in equity securities consisting of 142,749 shares of common stock of ONCO (the “ONCO Common Stock”), which were sold during the quarter ended December 31, 2024 September 30, 2024, three December 31, 2024 2023 The Company received 3,000 shares of Series A Convertible Preferred Stock (the “ONCO Preferred Stock”) of ONCO on October 3, 2023 September 30, 2023 15 825. 3 no no October 3, 2023. September 24, 2024, September 30, 2024, 1

Note 5 - Accounts Receivable

Note 5 - Accounts Receivable	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	Note 5 Accounts Receivable All of the Company's accounts receivables were included in the assets sold as part of the FC2 11 April 18, 2023.

Note 6 - Fixed Assets

Note 6 - Fixed Assets	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 6 Fixed Assets We record equipment, furniture and fixtures, and leasehold improvements at historical cost. Expenditures for maintenance and repairs are recorded to expense. Depreciation and amortization are primarily computed using the straight-line method. Depreciation and amortization are computed over the estimated useful lives of the respective assets. Leasehold improvements are depreciated on a straight-line basis over the lesser of the remaining lease term or the estimated useful lives of the improvements. Property and equipment consisted of the following at December 31, 2024 September 30, 2024 Estimated December 31, September 30, Useful Life (in years) 2024 2024 Property and equipment: Office equipment, furniture and fixtures 3 - 7 765,911 765,911 Leasehold improvements 8 199,532 199,532 Total property and equipment 965,443 965,443 Less: accumulated depreciation and amortization (513,400 ) (484,071 ) Property and equipment, net $ 452,043 $ 481,372 Depreciation expense was approximately $29,000 and $32,000 for the three December 31, 2024 2023

Note 7 - Goodwill

Note 7 - Goodwill	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Goodwill Disclosure [Text Block]	Note 7 Goodwill The carrying amount of goodwill at December 31, 2024 September 30, 2024 three December 31, 2024 2023

Note 8 - Debt

Note 8 - Debt	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 8 Debt SWK Residual Royalty Agreement On March 5, 2018, August 2021, In connection with the Credit Agreement, the Company and the Agent also entered into a Residual Royalty Agreement, dated as of March 5, 2018 FC2. FC2 FC2 x FC2 12 In connection with the closing of the FC2 December 30, 2024, 4 For accounting purposes, the $10.0 million advance under the Credit Agreement was allocated between the Credit Agreement and the Residual Royalty Agreement on a relative fair value basis. A portion of the amount allocated to the Residual Royalty Agreement, equal to the fair value of the respective change of control provisions, was allocated to the embedded derivative liability. The derivative liability was adjusted to fair market value at each reporting period. At December 31, 2024 September 30, 2024 December 31, September 30, 2024 2024 Residual royalty agreement liability, fair value at inception $ 346,000 $ 346,000 Add: accretion of liability using effective interest rate 13,149,689 12,985,419 Less: cumulative payments (5,357,616 ) (5,024,790 ) Less: extinguishments (8,138,073 ) — Residual royalty agreement liability, excluding embedded derivative liability — 8,306,629 Add: embedded derivative liability at fair value (see Note 4) — 1,570,000 Total residual royalty agreement liability — 9,876,629 Residual royalty agreement liability, short-term portion — (1,025,837 ) Residual royalty agreement liability, long-term portion $ — $ 8,850,792 Premium Finance Agreement On November 1, 2022, eleven December 1, 2022. September 30, 2023. October 2023 December 31, 2024 September 30, 2024.

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Equity [Text Block]	Note 9 Stockholders Equity Preferred Stock The Company has 5,000,000 authorized shares designated as Class A Preferred Stock with a par value of $0.01 per share. There are 1,040,000 shares of Class A Preferred Stock – Series 1 2 3 4 4 December 31, 2024 September 30, 2024 December 31, 2024 September 30, 2024 three December 31, 2024 2023 Shelf Registration Statement In March 2023, 3 No. 333 270606 April 14, 2023. December 31, 2024 10 December 31, 2023 8 February 27, 2024, not 3 No. 333 270606 3 no March 1, 2025, 1A, Common Stock Offering On December 18, 2023, 3 No. 333 270606 Lincoln Park Capital Fund LLC Purchase Agreement On May 2, 2023, may may one not December 13, 2023, 3 No. 333 270606 May 3, 2023, December 13, 2023 Under the Lincoln Park Purchase Agreement, the Company has the right, but not not 1 not not not three 10 4:00 In addition to Regular Purchases and provided that the Company has directed a Regular Purchase in full, the Company in its sole discretion may three may The purchase price of Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases and the minimum closing sale price for a Regular Purchase will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction occurring during the business days used to compute the purchase price. The aggregate number of shares that the Company can sell to Lincoln Park under the Lincoln Park Purchase Agreement may no no 5635 During the three December 31, 2024 not three December 31, 2023 December 31, 2024 In consideration for entering into the Lincoln Park Purchase Agreement, concurrently with the execution of the Lincoln Park Purchase Agreement, the Company issued 800,000 shares of the Company’s common stock to Lincoln Park. The shares of common stock issued as consideration were valued at $1.0 million, based on the closing price per share of the Company’s common stock on the date the shares were issued. This amount and related expenses of $57,000, which total approximately $1.1 million, were recorded as deferred costs. The unamortized deferred costs related to the Lincoln Park Purchase Agreement of $870,000 as of December 31, 2024 September 30, 2024 At-the-Market Sale Agreement On May 12, 2023, may not 3 No. 333 270606 May 12, 2023. August 19, 2024, September 3, 2024. not During the three December 31, 2023

Note 10 - Share-based Compensat

Note 10 - Share-based Compensation	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	Note 10 Share-based Compensation We allocate share-based compensation expense to selling, general and administrative expense and research and development expense based on the award holder’s employment function. For the three December 31, 2024 2023 Three Months Ended December 31, 2024 2023 Selling, general and administrative $ 2,004,716 $ 2,400,424 Research and development 679,438 483,379 Discontinued operations (10,049 ) 523,146 Share-based compensation $ 2,674,105 $ 3,406,949 We have issued share-based awards to employees and non-executive directors under the Company’s approved equity plans. Upon the exercise of share-based awards, new shares are issued from authorized common stock. Equity Plans In June 2022, 2022 December 31, 2024 In March 2018, 2018 “2018 March 29, 2022, may 2018 December 31, 2024 2018 In July 2017, 2017 “2017 2017 December 31, 2024 2017 2017 2008 “2008 2008 Stock Options Each option grants the holder the right to purchase from us one three may ten not three December 31, 2024 2023 The following table outlines the weighted average assumptions for options granted during the three December 31, 2024 2023 Three Months Ended December 31, 2024 2023 Weighted Average Assumptions: Expected volatility 109.9 % 104.0 % Expected dividend yield 0.0 % 0.0 % Risk-free interest rate 3.6 % 4.7 % Expected term (in years) 6.0 6.0 Fair value of options granted $ 0.64 $ 0.60 During the three December 31, 2024 2023 zero The following table summarizes the stock options outstanding and exercisable at December 31, 2024 Weighted Average Remaining Aggregate Number of Exercise Price Contractual Term Intrinsic Shares Per Share (years) Value Outstanding at September 30, 2024 18,462,428 $ 4.59 Granted 240,000 $ 0.77 Exercised — $ — Forfeited and expired (554,867 ) $ 5.52 Outstanding at December 31, 2024 18,147,561 $ 4.51 5.76 $ 16,944 Exercisable at December 31, 2024 14,133,583 $ 4.76 4.92 $ — The aggregate intrinsic values in the table above are before income taxes and represent the number of in-the-money options outstanding or exercisable multiplied by the closing price per share of the Company’s common stock on the last trading day of the quarter ended December 31, 2024 As of December 31, 2024 Stock Appreciation Rights In connection with the closing of our acquisition of Aspen Park Pharmaceuticals, Inc. on October 31, 2016 October 31, 2018. ten 2017 December 31, 2024

Note 11 - Leases

Note 11 - Leases	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 11 Leases The Company has operating leases for its office and office equipment. The Company’s leases have remaining lease terms of less than three six one October 31, 2023. not not December 31, 2024 The components of the Company’s lease cost were as follows for the three December 31, 2024 2023 Three Months Ended December 31, 2024 2023 Operating lease cost $ 186,233 $ 188,223 Short-term lease cost 2,541 2,541 Variable lease cost 1,318 13,965 Sublease income — (15,148 ) Total lease cost $ 190,092 $ 189,581 The Company paid cash of $188,000 and $192,000 for amounts included in the measurement of operating lease liabilities during the three December 31, 2024 2023 The Company’s operating lease right-of-use assets and the related lease liabilities are presented as separate line items on the accompanying unaudited condensed consolidated balance sheets as of December 31, 2024 September 30, 2024 Other information related to the Company’s leases as of December 31, 2024 September 30, 2024 December 31, September 30, 2024 2024 Operating Leases Weighted-average remaining lease term (years) 5.2 5.4 Weighted-average discount rate 7.1 % 7.1 % The Company’s lease agreements do not

Note 12 - Contingent Liabilitie

Note 12 - Contingent Liabilities	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 12 Contingent Liabilities The testing, manufacturing and marketing of consumer products by the Company and the clinical testing of our product candidates entail an inherent risk that product liability claims will be asserted against the Company. The Company maintains product liability insurance coverage for claims arising from the use of its products. The coverage amount is currently $10.0 million. Legal Proceedings On December 5, 2022, No. 1:22 23960 September 15, 2023 19 March 1, 2021 March 2, 2023 10 20 1934 10b 5 On July 7, 2023, No. 2023 019406 01 On September 1, 2023, No. 2:23 01164 November 8, 2023, On September 28, 2023, No. 2:23 01291 November 8, 2023, On October 9, 2023, No. 1:23 23846 On September 30, 2024, June No. 3:24 00676 The Ewing Lawsuit, Maglia Lawsuit, Franchi Lawsuit, Renbarger Lawsuit, Alshourbagy Lawsuit and the Ovadias Lawsuit are collectively referred to as the “Shareholder Litigation.” At this time, the Company is unable to estimate potential losses, if any, related to the Shareholder Litigation. License and Purchase Agreements From time to time, we license or purchase rights to technology or intellectual property from third may not not Resolution of Commercial Dispute A supplier claimed that we owed approximately $10 million for products and services relating to our efforts to commercialize sabizabulin under an EUA. We disputed the amount owed and on February 29, 2024, December 31, 2025 may April 2024 September 2024. December 31, 2025, January 2026. December 31, 2024

Note 13 - Income Taxes

Note 13 - Income Taxes	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 13 Income Taxes The Company accounts for income taxes using the liability method, which requires the recognition of deferred tax assets or liabilities for the tax-effected temporary differences between the financial reporting and tax bases of its assets and liabilities, and for net operating loss (NOL) and tax credit carryforwards. A reconciliation of income tax expense, which is zero as a result of the Company’s full valuation allowance for deferred tax assets, and the amount computed by applying the U.S. statutory rate of 21% to loss from continuing operations is as follows: Three Months Ended December 31, 2024 2023 Income tax benefit at U.S. federal statutory rates $ (380,080 ) $ (1,610,150 ) State income tax benefit, net of federal benefit (29,429 ) (124,672 ) Non-deductible expenses 739 112 U.S. research and development tax credit (230,797 ) (170,000 ) Change in valuation allowance 639,567 1,904,710 Income tax expense $ — $ —

Note 14 - Net Loss Per Share

Note 14 - Net Loss Per Share	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 14 Net Loss Per Share Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period after giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of the incremental common shares issuable upon the exercise of stock options and stock appreciation rights. Due to our net loss for the periods presented, all potentially dilutive instruments were excluded because their inclusion would have been anti-dilutive. See Note 10

Note 15 - Sale of ENTADFI Asset

Note 15 - Sale of ENTADFI Assets	3 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Disposal Groups, Not Discontinued Operations, Disclosure [Text Block]	Note 15 Sale of ENTADFI Assets On April 19, 2023, December 2021, April 19, 2023. September 30, 2023, April 19, 2024 “April 2024 September 30, 2024 ( “September 2024 April 2024 On September 29, 2023, September 30, 2023 1 September 29, 2023 2 October 3, 2023 September 29, 2023 October 3, 2023, October 3, 2023 one September 5, 2024. September 24, 2024, one forty 1:40 September 24, 2024, three December 31, 2024 On April 24, 2024, April 2024 not April 29, 2024, April 25, 2024, April 2024 April 19, 2024, may may April 24, 2024 March 31, 2025 not ONCO agreed in the Forbearance Agreement to make the following required payments during the Forbearance Period towards the remaining principal balance of the April 2024 1 2 On September 19, 2024, September 2024 Pursuant to the Amended Forbearance Agreement, the forbearance period relating to the Company’s agreement to forbear from exercising its rights and remedies on account of the failure by the Borrower to pay the amounts due under the April 2024 April 19, 2024 March 31, 2025 “April 2024 September June 30, 2025 September 2024 The Borrower agreed in the Amended Forbearance Agreement to make the following required payments (the “Required Payments”) during the April 2024 first April 2024 April 2024 ● monthly payments equal to 25% (increased from 15% in the Original Forbearance Agreement) of cash receipts of the Borrower or its subsidiaries from certain sale or licensing revenues or payments, which increased amount shall begin on October 20, 2024 September 2024; ● payment of 20% (increased from 10% in the Original Forbearance Agreement) of the net proceeds from certain financing or other transactions outside the ordinary course of business completed by the Borrower or any of its subsidiaries during the April 2024 September 19, 2024. The remaining balance of the April 2024 April 2024 The Borrower and the Company also agreed to the following amendments to the September 2024 ● As noted above, an extension of the maturity date to June 30, 2025. ● The accrual of interest at the rate of 10% per annum on any unpaid principal balance of the September 2024 October 1, 2024 September 2024 ● Any amounts owed on the September 2024 not ● Following full repayment of all principal and interest under the April 2024 first September 2024 September 2024 ● If the aggregate unpaid principal outstanding under the April 2024 September 2024 December 31, 2024, September 2024 September 2024 The Company and ONCO entered into a Waiver and Amendment No. 1 November 26, 2024, x The Company determined that it was not December 31, 2024 three December 31, 2024 2023

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Insider Trading Arr Line Items
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of consolidation and nature of operations December 30, 2024, FC2 3 December 30, 2024. December 31, 2024 not FC2 Condom/FC2 FC2 FC2 December 30, 2024. 3 December 2021. April 19, 2023. 15 three December 31, 2024 2023 FC2
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications no
Comprehensive Income, Policy [Policy Text Block]	Other comprehensive loss three December 31, 2024 2023
New Accounting Pronouncements, Policy [Policy Text Block]	Recent accounting pronouncements not November 2023, 2023 07, 280 2023 07 September 30, 2025, In December 2023, 2023 09, 740 2023 09 September 30, 2026, In November 2024, 2024 03, 220 40 January 2025, 2025 01 2024 03. 2024 03 September 30, 2028, 2024 03 We have reviewed all other recently issued accounting pronouncements and have determined that such standards that are not not not

Note 3 - Discontinued Operati_2

Note 3 - Discontinued Operations (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	Three Months Ended December 31, 2024 2023 Net revenues $ 4,484,591 $ 2,140,726 Cost of sales 2,900,514 990,274 Gross profit 1,584,077 1,150,452 Operating expenses: Selling, general and administrative 1,101,987 1,641,283 Total operating expenses 1,101,987 1,641,283 Loss on sale of FC2 business (4,204,435 ) — Operating loss (3,722,345 ) (490,831 ) Non-operating expenses: Interest expense (164,270 ) (164,957 ) Change in fair value of derivative liabilities (3,138,316 ) (2,000 ) Other expense, net (31,960 ) (23,249 ) Total non-operating expenses (3,334,546 ) (190,206 ) Loss before income taxes (7,056,891 ) (681,037 ) Income tax expense (benefit) 78,553 (72,439 ) Net loss from discontinued operations, net of taxes $ (7,135,444 ) $ (608,598 )
Schedule of Disposal Groups, Including Discontinued Operations, Balance Sheet [Table Text Block]	September 30, 2024 Current assets: Accounts receivable, net $ 3,960,305 Inventories, net 4,144,179 Prepaid expenses and other current assets 654,527 Total current assets of discontinued operations $ 8,759,011 Long-term assets: Plant and equipment, net $ 803,282 Operating lease right-of-use asset 311,150 Deferred income taxes 12,340,237 Other assets 140,356 Total long-term assets of discontinued operations $ 13,595,025 Current liabilities: Accounts payable $ 777,173 Accrued compensation 185,418 Accrued expenses and other current liabilities 1,390,412 Operating lease liability, short-term portion 328,527 Total current liabilities of discontinued operations $ 2,681,530 Long-term liabilities: Operating lease liability, long-term portion $ 16,071 Long-term liabilities of discontinued operations $ 16,071
Schedule of Disposal Groups, Including Discontinued Operations, Cash Flow Information [Table Text Block]	Three Months Ended December 31, 2024 2023 Total net cash (used in) provided by operating activities from discontinued operations $ (325,454 ) $ 1,525,846 Total net cash provided by investing activities from discontinued operations $ 16,156,882 $ —

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three Months Ended December 31, 2024 2023 Beginning balance $ 1,570,000 $ 1,331,000 Change in fair value of derivative liabilities 3,138,316 2,000 Extinguishments (4,708,316 ) — Ending balance $ — $ 1,333,000
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Valuation Methodology Significant Unobservable Input December 30, 2024 September 30, 2024 Scenario-Based Estimated change of control dates December 2024 March 2025 to March 2027 Discount rate N/A 12.1% to 12.3% Probability of change of control 100 % 60% to 90%

Note 6 - Fixed Assets (Tables)

Note 6 - Fixed Assets (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	Estimated December 31, September 30, Useful Life (in years) 2024 2024 Property and equipment: Office equipment, furniture and fixtures 3 - 7 765,911 765,911 Leasehold improvements 8 199,532 199,532 Total property and equipment 965,443 965,443 Less: accumulated depreciation and amortization (513,400 ) (484,071 ) Property and equipment, net $ 452,043 $ 481,372

Note 8 - Debt (Tables)

Note 8 - Debt (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Debt [Table Text Block]	December 31, September 30, 2024 2024 Residual royalty agreement liability, fair value at inception $ 346,000 $ 346,000 Add: accretion of liability using effective interest rate 13,149,689 12,985,419 Less: cumulative payments (5,357,616 ) (5,024,790 ) Less: extinguishments (8,138,073 ) — Residual royalty agreement liability, excluding embedded derivative liability — 8,306,629 Add: embedded derivative liability at fair value (see Note 4) — 1,570,000 Total residual royalty agreement liability — 9,876,629 Residual royalty agreement liability, short-term portion — (1,025,837 ) Residual royalty agreement liability, long-term portion $ — $ 8,850,792

Note 10 - Share-based Compens_2

Note 10 - Share-based Compensation (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended December 31, 2024 2023 Selling, general and administrative $ 2,004,716 $ 2,400,424 Research and development 679,438 483,379 Discontinued operations (10,049 ) 523,146 Share-based compensation $ 2,674,105 $ 3,406,949
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended December 31, 2024 2023 Weighted Average Assumptions: Expected volatility 109.9 % 104.0 % Expected dividend yield 0.0 % 0.0 % Risk-free interest rate 3.6 % 4.7 % Expected term (in years) 6.0 6.0 Fair value of options granted $ 0.64 $ 0.60
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Average Remaining Aggregate Number of Exercise Price Contractual Term Intrinsic Shares Per Share (years) Value Outstanding at September 30, 2024 18,462,428 $ 4.59 Granted 240,000 $ 0.77 Exercised — $ — Forfeited and expired (554,867 ) $ 5.52 Outstanding at December 31, 2024 18,147,561 $ 4.51 5.76 $ 16,944 Exercisable at December 31, 2024 14,133,583 $ 4.76 4.92 $ —

Note 11 - Leases (Tables)

Note 11 - Leases (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended December 31, 2024 2023 Operating lease cost $ 186,233 $ 188,223 Short-term lease cost 2,541 2,541 Variable lease cost 1,318 13,965 Sublease income — (15,148 ) Total lease cost $ 190,092 $ 189,581
Lessee, Operating Lease [Table Text Block]	December 31, September 30, 2024 2024 Operating Leases Weighted-average remaining lease term (years) 5.2 5.4 Weighted-average discount rate 7.1 % 7.1 %

Note 13 - Income Taxes (Tables)

Note 13 - Income Taxes (Tables)	3 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Three Months Ended December 31, 2024 2023 Income tax benefit at U.S. federal statutory rates $ (380,080 ) $ (1,610,150 ) State income tax benefit, net of federal benefit (29,429 ) (124,672 ) Non-deductible expenses 739 112 U.S. research and development tax credit (230,797 ) (170,000 ) Change in valuation allowance 639,567 1,904,710 Income tax expense $ — $ —

Note 3 - Discontinued Operati_3

Note 3 - Discontinued Operations (Details Textual) - USD ($)		3 Months Ended
	Dec. 30, 2024	Dec. 31, 2024	Dec. 31, 2023	Sep. 30, 2024
Proceeds from Divestiture of Businesses, Net of Cash Divested		$ 16,157,965	$ 0
Payment for Debt Extinguishment or Debt Prepayment Cost		4,221,611	0
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal		695,216	$ 918,372
Residual Royalty Financing Agreement [Member]
Payment for Debt Extinguishment or Debt Prepayment Cost	$ 4,200,000
FC2 Female Condom [Member] | Discontinued Operations, Disposed of by Sale [Member]
Disposal Group, Including Discontinued Operation, Consideration	18,000,000
Proceeds from Divestiture of Businesses, Net of Cash Divested	16,400,000
Disposal Group, Including Discontinued Operation, Transaction Cost	1,400,000
Disposal Group, Including Discontinued Operation Consideration, Adjustment	100,000
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	(4,200,000)
Disposal Group, Including Discontinued Operation, Assets (Liabilities), Net	20,600,000
Disposal Group, Including Discontinued Operation, Deferred Tax Assets				$ 12,340,237
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net				$ 3,960,305
Disposal Group, Including Discontinued Operation, Assets		0
Disposal Group, Including Discontinued Operation, Liabilities		0
FC2 Female Condom [Member] | Discontinued Operations, Disposed of by Sale [Member] | Cash [Member]
Escrow Deposit	$ 400,000	$ 400,000
Escrow Deposit, Term (Month)	18 months
FC2 Female Condom [Member] | Discontinued Operations, Disposed of by Sale [Member] | Restricted Cash, Payment Adjustments [Member]
Escrow Deposit	$ 300,000
FC2 Female Condom [Member] | Discontinued Operations, Disposed of by Sale [Member] | Restricted Cash, Indemnity Obligations [Member]
Escrow Deposit	100,000
FC2 Female Condom [Member] | Discontinued Operations, Disposed of by Sale [Member] | Reported Value Measurement [Member]
Disposal Group, Including Discontinued Operation, Deferred Tax Assets	12,300,000
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net	4,600,000
Disposal Group, Including Discontinued Operation, Inventory	3,400,000
Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current	1,500,000
FC2 Female Condom [Member] | Discontinued Operations, Disposed of by Sale [Member] | Residual Royalty Financing Agreement [Member]
Payment for Debt Extinguishment or Debt Prepayment Cost	4,200,000
FC2 Female Condom [Member] | Discontinued Operations, Disposed of by Sale [Member] | Transition Services Agreement [Member]
Disposal Group, Including Discontinued Operation, Consideration	200,000
Professional Fees	0
FC2 Female Condom [Member] | Discontinued Operations, Disposed of by Sale [Member] | Transition Services Agreement [Member] | Supply Commitment [Member]
Disposal Group, Including Discontinued Operation, Consideration	$ 200,000
FC2 Female Condom [Member] | Discontinued Operations, Disposed of by Sale [Member] | Transition Services Agreement [Member] | Minimum [Member]
Contractual Obligation Term (Month)	6 months
FC2 Female Condom [Member] | Discontinued Operations, Disposed of by Sale [Member] | Transition Services Agreement [Member] | Maximum [Member]
Contractual Obligation Term (Month)	32 months

Note 3 - Discontinued Operati_4

Note 3 - Discontinued Operations - Schedule of Disposal Groups (Details) - USD ($)	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Loss on sale of FC2 business	$ (4,204,435)	$ 0
Net loss from discontinued operations, net of taxes	(7,135,444)	(608,598)
FC2 Female Condom [Member] | Discontinued Operations, Disposed of by Sale [Member]
Net revenues	4,484,591	2,140,726
Cost of sales	2,900,514	990,274
Gross profit	1,584,077	1,150,452
Selling, general and administrative	1,101,987	1,641,283
Total operating expenses	1,101,987	1,641,283
Loss on sale of FC2 business	(4,204,435)	0
Operating loss	(3,722,345)	(490,831)
Interest expense	(164,270)	(164,957)
Change in fair value of derivative liabilities	(3,138,316)	(2,000)
Other expense, net	(31,960)	(23,249)
Total non-operating expenses	(3,334,546)	(190,206)
Loss before income taxes	(7,056,891)	(681,037)
Income tax expense (benefit)	78,553	(72,439)
Net loss from discontinued operations, net of taxes	$ (7,135,444)	$ (608,598)

Note 3 - Discontinued Operati_5

Note 3 - Discontinued Operations - Schedule of Disposal Groups - Balance Sheet (Details) - USD ($)	Dec. 31, 2024	Sep. 30, 2024
Total current assets of discontinued operations	$ 0	$ 8,759,011
Total long-term assets of discontinued operations	0	13,595,025
Total current liabilities of discontinued operations	0	2,681,530
Long-term liabilities of discontinued operations	$ 0	16,071
FC2 Female Condom [Member] | Discontinued Operations, Disposed of by Sale [Member]
Accounts receivable, net		3,960,305
Inventories, net		4,144,179
Prepaid expenses and other current assets		654,527
Total current assets of discontinued operations		8,759,011
Plant and equipment, net		803,282
Operating lease right-of-use asset		311,150
Deferred income taxes		12,340,237
Other assets		140,356
Total long-term assets of discontinued operations		13,595,025
Accounts payable		777,173
Accrued compensation		185,418
Accrued expenses and other current liabilities		1,390,412
Operating lease liability, short-term portion		328,527
Total current liabilities of discontinued operations		2,681,530
Operating lease liability, long-term portion		16,071
Long-term liabilities of discontinued operations		$ 16,071

Note 3 - Discontinued Operati_6

Note 3 - Discontinued Operations - Schedule of Disposal Groups - Statements of Cash Flows (Details) - FC2 Female Condom [Member] - Discontinued Operations, Disposed of by Sale [Member] - USD ($)	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Total net cash (used in) provided by operating activities from discontinued operations	$ (325,454)	$ 1,525,846
Total net cash provided by investing activities from discontinued operations	$ 16,156,882	$ 0

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurements (Details Textual)	3 Months Ended
	Dec. 31, 2024 USD ($) shares	Dec. 31, 2023 USD ($)	Oct. 03, 2024 yr shares	Sep. 30, 2024 USD ($)	Sep. 24, 2024 shares	Oct. 03, 2023 USD ($)
Proceeds from Sale of Equity Securities, FV-NI	$ 393,217	$ 0
Equity Securities, FV-NI, Unrealized Gain (Loss)	$ (349,078)	(379,898)
Fair Value, Inputs, Level 3 [Member] | Preferred Stock [Member] | Measurement Input, Discount Rate [Member] | ONCO [Member]
Equity Securities, FV-NI, Measurement Input			0.35
ONCO [Member] | Fair Value, Inputs, Level 3 [Member] | Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Equity Securities, FV-NI, Measurement Input			0.79
ONCO [Member] | Fair Value, Inputs, Level 3 [Member] | Preferred Stock [Member] | Measurement Input, Expected Term [Member]
Equity Securities, FV-NI, Measurement Input | yr			3
ONCO [Member] | Fair Value, Inputs, Level 3 [Member] | Preferred Stock [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Equity Securities, FV-NI, Measurement Input			0.15
ONCO [Member] | Fair Value, Inputs, Level 3 [Member] | Preferred Stock [Member] | Measurement Input, Probability Of Dissolution [Member[
Equity Securities, FV-NI, Measurement Input			0.60
Common Stock [Member] | ONCO [Member]
Investment Owned, Balance, Shares (in shares) | shares	142,749				142,749
Proceeds from Sale of Equity Securities, FV-NI	$ 400,000
Investment Owned, Balance, Principal Amount				$ 700,000
Equity Securities, FV-NI, Unrealized Gain (Loss)	$ (300,000)	$ (400,000)
Series A Convertible Preferred Stock [Member] | ONCO [Member]
Investment Owned, Balance, Shares (in shares) | shares			3,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value						$ 900,000

Note 4 - Fair Value Measureme_4

Note 4 - Fair Value Measurements - Schedule of Reconciliation of Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Inputs, Level 3 [Member] - Embedded Derivative Financial Instruments [Member] - USD ($)	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Balance	$ 1,570,000	$ 1,331,000
Change in fair value of derivative liabilities	3,138,316	2,000
Extinguishments	(4,708,316)	0
Balance	$ 0	$ 1,333,000

Note 4 - Fair Value Measureme_5

Note 4 - Fair Value Measurements - Schedule of Valuation Approach and Technique (Details) - Fair Value, Inputs, Level 3 [Member] - Embedded Derivative Financial Instruments [Member] - Valuation, Scenario-based [Member]	Dec. 30, 2024	Sep. 30, 2024
Minimum [Member] | Measurement Input, Discount Rate [Member]
Measurement input		0.121
Minimum [Member] | Measurement Input, Probability of Change of Control [Member]
Measurement input	1	0.60
Maximum [Member] | Measurement Input, Discount Rate [Member]
Measurement input		0.123
Maximum [Member] | Measurement Input, Probability of Change of Control [Member]
Measurement input		0.90

Note 5 - Accounts Receivable (D

Note 5 - Accounts Receivable (Details Textual) $ in Millions	Dec. 31, 2024 USD ($)
The Pill Club [Member] | Unlikely to be Collected Financing Receivable [Member]
Accounts Receivable, Allowance for Credit Loss	$ 3.9

Note 6 - Fixed Assets (Details

Note 6 - Fixed Assets (Details Textual) - USD ($)	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Depreciation	$ 29,000	$ 32,000

Note 6 - Fixed Assets - Schedul

Note 6 - Fixed Assets - Schedule of Plant and Equipment (Details) - USD ($)	Dec. 31, 2024	Sep. 30, 2024
Plant and equipment	$ 965,443	$ 965,443
Less: accumulated depreciation and amortization	(513,400)	(484,071)
Property and equipment, net	452,043	481,372
Office Equipment, Furniture and Fixtures [Member]
Plant and equipment	$ 765,911	765,911
Office Equipment, Furniture and Fixtures [Member] | Minimum [Member]
Plant and equipment, useful life (Year)	3 years
Office Equipment, Furniture and Fixtures [Member] | Maximum [Member]
Plant and equipment, useful life (Year)	7 years
Leasehold Improvements [Member]
Plant and equipment, useful life (Year)	8 years
Plant and equipment	$ 199,532	$ 199,532

Note 7 - Goodwill (Details Text

Note 7 - Goodwill (Details Textual) - USD ($)	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Sep. 30, 2024
Goodwill	$ 6,878,932	$ 6,900,000	$ 6,878,932
Goodwill, Period Increase (Decrease)	$ 0	$ 0

Note 8 - Debt (Details Textual)

Note 8 - Debt (Details Textual) - USD ($)			3 Months Ended
	Dec. 30, 2024	Mar. 05, 2018	Dec. 31, 2024	Dec. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Nov. 01, 2022
Payment for Debt Extinguishment or Debt Prepayment Cost			$ 4,221,611	$ 0
Gain (Loss) on Extinguishment of Debt			8,624,778	$ 0
Credit Agreement [Member]
Debt Instrument, Face Amount		$ 10,000,000
Long-Term Debt		$ 0
Residual Royalty Financing Agreement [Member]
Royalty Agreement, Payment, Percentage		5%
Payment for Debt Extinguishment or Debt Prepayment Cost	$ 4,200,000
Gain (Loss) on Extinguishment of Debt	$ 8,600,000
Residual Royalty Financing Agreement [Member] | Scenario, Change of Control or Sale of Business [Member]
Royalty Agreement, Payment, Percentage		5%
Royalty Agreement, Payment to Agent		$ 2,000,000
Credit Agreement and Residual Royalty Financing Agreement [Member]
Debt Instrument, Face Amount		$ 10,000,000
Premium Finance Agreement [Member]
Debt Instrument, Face Amount							$ 1,400,000
Debt Instrument, Interest Rate, Stated Percentage							6.30%
Accrued Liabilities and Other Liabilities			$ 0		$ 0	$ 100,000

Note 8 - Debt - Schedule of Res

Note 8 - Debt - Schedule of Residual Royalty Agreement Liability (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024
Residual royalty agreement liability, fair value at inception	$ 346,000	$ 346,000
Add: accretion of liability using effective interest rate	13,149,689	12,985,419
Less: cumulative payments	(5,357,616)	(5,024,790)
Less: extinguishments	(8,138,073)	0
Residual royalty agreement liability, excluding embedded derivative liability	0	8,306,629
Add: embedded derivative liability at fair value (see Note 4)	0	1,570,000
Total residual royalty agreement liability	0	9,876,629
Residual royalty agreement liability, short-term portion	0	(1,025,837)
Residual royalty agreement liability, long-term portion	$ 0	$ 8,850,792

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Details Textual) - USD ($)						3 Months Ended		20 Months Ended
	May 02, 2024	Dec. 18, 2023	Dec. 13, 2023	May 12, 2023	May 02, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Sep. 30, 2024	Mar. 31, 2023
Preferred Stock, Shares Issued (in shares)						0		0	0
Security Offering, Maximum Value of Securities, Shelf Registration										$ 200,000,000
Security Offering, Remaining Value of Securities, Shelf Registration						$ 109,000,000		$ 109,000,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs							$ 164,313
Preferred Stock, Shares Outstanding (in shares)						0		0	0
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)		52,708,332
Shares Issued, Price Per Share (in dollars per share)		$ 0.72
Proceeds from Issuance or Sale of Equity		$ 35,200,000				$ 0	35,378,888
Stock Issued During Period, Value, New Issues							$ 35,229,415
Lincoln Park Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)						0	1,800,000	3,025,000
Proceeds from Issuance or Sale of Equity						$ 0	$ 1,661,490
Shares Purchase Agreement, Value, Shares Authorized			$ 50,000,000		$ 100,000,000
Share Purchase Agreement, Term (Month)					36 months
Shares Purchase Agreement, Shares Authorized (in shares)					225,000
Shares Purchase Agreement, Value, Maximum Commitment					$ 2,500,000
Shares Purchase Agreement, Shares, Maximum Commitment (in shares)					2,000,000
Shares Purchase Agreement, Accelerated Purchase Date, Percent Of Trading Volume					30%
Shares Purchase Agreement, Accelerated Purchase Date, Purchase Price, Percent					97%
Shares Purchase Agreement, Shares Authorized, Aggregate Maximum (in shares)					17,678,502
Shares Purchase Agreement, Shares Authorized, Percentage of Common Shares Oustanding					19.99%
Stock Issued During Period, Value, New Issues							1,661,490	$ 3,100,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs							164,000
Stock Issued During Period, Shares, Issued for Services (in shares)	800,000
Stock Issued During Period, Value, Issued for Services	$ 1,000,000
Deferred Offering Costs	57,000
Deferred Costs	$ 1,100,000
Unamortized Debt Issuance Expense						$ 870,000		$ 870,000	$ 870,000
Lincoln Park Purchase Agreement [Member] | Shares Required to be Purchased if Closing Price is $6.00 or Above [Member]
Shares Issued, Price Per Share (in dollars per share)					$ 6
Shares Purchase Agreement, Shares Authorized (in shares)					250,000
Lincoln Park Purchase Agreement [Member] | Shares Required to be Purchased if Closing Price is $8.00 or Above [Member]
Shares Issued, Price Per Share (in dollars per share)					$ 8
Shares Purchase Agreement, Shares Authorized (in shares)					275,000
Lincoln Park Purchase Agreement [Member] | Maximum [Member]
Shares Issued, Price Per Share (in dollars per share)					$ 0.25
Shares Purchase Agreement, Value, Shares Authorized			50,000,000		$ 100,000,000
Lincoln Park Purchase Agreement [Member] | Minimum [Member]
Shares Purchase Agreement, Value, Shares Authorized			$ 50,000,000
Lincoln Park Purchase Agreement [Member] | Weighted Average [Member]
Shares Issued, Price Per Share (in dollars per share)					$ 1.26
Jefferies Sales Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)						90,156
Proceeds from Issuance or Sale of Equity						$ 0	66,551
Shares Purchase Agreement, Value, Shares Authorized				$ 75,000,000
Stock Issued During Period, Value, New Issues						$ 67,000	$ 66,551
Common Stock, Capital Shares Reserved for Future Issuance (in shares)				39,609,072
Preferred Class A [Member]
Preferred Stock, Shares Authorized (in shares)						5,000,000		5,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)						$ 0.01		$ 0.01
Preferred Stock, Shares Issued (in shares)						0	0	0
Preferred Stock, Shares Outstanding (in shares)						0	0	0
Preferred Class, Series A-1 [Member]
Preferred Stock, Shares Authorized (in shares)						1,040,000		1,040,000
Preferred Class, Series A-2 [Member]
Preferred Stock, Shares Authorized (in shares)						1,500,000		1,500,000
Preferred Class, Series A-3 [Member]
Preferred Stock, Shares Authorized (in shares)						700,000		700,000
Preferred Class, Series A-4 [Member]
Preferred Stock, Shares Authorized (in shares)						548,000		548,000
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)						15,000		15,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)						$ 0.5		$ 0.5
Preferred Stock, Shares Issued (in shares)						0	0	0
Stock Issued During Period, Shares, Period Increase (Decrease) (in shares)						0
Preferred Stock, Shares Outstanding (in shares)						0	0	0
Preferred Stock [Member]
Stock Issued During Period, Shares, Period Increase (Decrease) (in shares)							0

Note 10 - Share-based Compens_3

Note 10 - Share-based Compensation (Details Textual) - USD ($)		1 Months Ended	3 Months Ended
	Oct. 31, 2016	Oct. 31, 2016	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2022	Mar. 31, 2018	Jul. 31, 2017
Share-Based Payment Arrangement, Expense			$ 2,674,105	$ 3,406,949
Share Price (in dollars per share)			$ 0.65
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)			3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)			10 years
Share-Based Payment Arrangement, Expense			$ 300,000	$ 1,100,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount			$ 7,700,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			1 year 8 months 12 days
Stock Appreciation Rights (SARs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)		10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)		$ 0.95
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)			50,000
Stock Appreciation Rights (SARs) [Member] | Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		50,000
Stock Appreciation Rights (SARs) [Member] | Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	140,000
The 2022 Employment Inducement Equity Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)					4,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)			4,000,000
The 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)			1,911,246
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)						18,500,000
The 2017 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)			198,948
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)							4,700,000
The 2008 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)							0

Note 10 - Share-based Compens_4

Note 10 - Share-based Compensation - Schedule of Allocated Expense (Details) - USD ($)	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-based compensation expense	$ 2,674,105	$ 3,406,949
FC2 Female Condom [Member] | Discontinued Operations, Disposed of by Sale [Member]
Share-based compensation expense, discontinued operations	(10,049)	523,146
Selling, General and Administrative Expenses [Member]
Share-based compensation expense	2,004,716	2,400,424
Research and Development Expense [Member]
Share-based compensation expense	$ 679,438	$ 483,379

Note 10 - Share-based Compens_5

Note 10 - Share-based Compensation of Assumptions (Details) - $ / shares	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Expected volatility	109.90%	104%
Expected dividend yield	0%	0%
Risk-free interest rate	3.60%	4.70%
Expected term (in years) (Year)	6 years	6 years
Fair value of options granted (in dollars per share)	$ 0.64	$ 0.6

Note 10 - Share-based Compens_6

Note 10 - Share-based Compensation - Schedule of Options (Details)	3 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares
Outstanding, balance (in shares) | shares	18,462,428
Outstanding, exercise price (in dollars per share) | $ / shares	$ 4.59
Granted (in shares) | shares	240,000
Granted, exercise price (in dollars per share) | $ / shares	$ 0.77
Exercised (in shares) | shares	0
Exercised, exercise price (in dollars per share) | $ / shares	$ 0
Forfeited and expired (in shares) | shares	(554,867)
Forfeited and expired, exercise price (in dollars per share) | $ / shares	$ 5.52
Outstanding, balance (in shares) | shares	18,147,561
Outstanding, exercise price (in dollars per share) | $ / shares	$ 4.51
Outstanding, remaining contractual term (Year)	5 years 9 months 3 days
Outstanding, intrinsic value | $	$ 16,944
Exercisable (in shares) | shares	14,133,583
Exercisable, exercise price (in dollars per share) | $ / shares	$ 4.76
Exercisable, remaining contractual term (Year)	4 years 11 months 1 day
Exercisable, intrinsic value | $	$ 0

Note 11 - Leases (Details Textu

Note 11 - Leases (Details Textual) - USD ($) Pure in Thousands	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating Lease, Payments	$ 188,000	$ 192,000
Lessee, Operating Lease, Discount Rate	0%
Minimum [Member]
Lessee, Operating Lease, Remaining Lease Term (Year)	3 years
Maximum [Member]
Lessee, Operating Lease, Remaining Lease Term (Year)	6 years

Note 11 - Leases - Schedule of

Note 11 - Leases - Schedule of Lease Cost (Details) - USD ($)	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating lease cost	$ 186,233	$ 188,223
Short-term lease cost	2,541	2,541
Variable lease cost	1,318	13,965
Sublease income	0	(15,148)
Total lease cost	$ 190,092	$ 189,581

Note 11 - Leases - Schedule o_2

Note 11 - Leases - Schedule of Operating Leases (Details)	Dec. 31, 2024	Sep. 30, 2024
Weighted-average remaining lease term (years) (Year)	5 years 2 months 12 days	5 years 4 months 24 days
Weighted-average discount rate	7.10%	7.10%

Note 12 - Contingent Liabilit_2

Note 12 - Contingent Liabilities (Details Textual) - USD ($)		3 Months Ended
	Feb. 29, 2024	Dec. 31, 2024	Sep. 30, 2024
Accounts Payable, Current		$ 1,994,645	$ 2,259,668
Other Liabilities, Noncurrent		4,078,187	4,461,920
Damages from Product Defects [Member]
Product Liability Contingency, Loss Exposure Not Accrued, Best Estimate		10,000,000
Loss Contingency, License and Purchase Agreements [Member]
Loss Contingency Accrual			$ 0
Loss Contingency, Commercial Dispute [Member] | Research and Development Liability [Member]
Accounts Payable, Current		1,000,000
Other Liabilities, Noncurrent		$ 4,100,000
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member]
Loss Contingency, Damages Sought, Value	$ 10,000,000
Loss Contingency Accrual, Product Liability, Net	8,300,000
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Due Upon Execution of Agreement [Member]
Loss Contingency Accrual, Product Liability, Net	2,300,000
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Monthly Installments,One [Member]
Loss Contingency Accrual, Product Liability, Net	$ 3,500,000
Product Liability Contingency, Disbursement Period, Estimate, Accrued (Month)	48 months
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Balance by December 31, 2025 [Member]
Loss Contingency Accrual, Product Liability, Net	$ 2,500,000
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Monthly Installments, Two [Member]
Product Liability Contingency, Disbursement Period, Estimate, Accrued (Month)	24 months

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($)	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Income Tax Expense (Benefit)	$ 0	$ 0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%

Note 13 - Income Taxes - Schedu

Note 13 - Income Taxes - Schedule of Reconciliation (Details) - USD ($)	3 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Income tax benefit at U.S. federal statutory rates	$ (380,080)	$ (1,610,150)
State income tax benefit, net of federal benefit	(29,429)	(124,672)
Non-deductible expenses	739	112
U.S. research and development tax credit	(230,797)	(170,000)
Change in valuation allowance	639,567	1,904,710
Income tax expense	$ 0	$ 0

Note 15 - Sale of ENTADFI Ass_2

Note 15 - Sale of ENTADFI Assets (Details Textual)							3 Months Ended
	Nov. 26, 2024 USD ($)	Sep. 30, 2024	Sep. 24, 2024 shares	Apr. 24, 2024 USD ($)	Sep. 29, 2023 USD ($) $ / shares shares	Apr. 19, 2023 USD ($)	Dec. 31, 2024 USD ($) shares	Dec. 31, 2023 USD ($)	Sep. 19, 2024 USD ($)
Proceeds from Sale of Productive Assets							$ 695,216	$ 0
Noncash or Part Noncash Divestiture, Amount of Consideration Received							0	918,372
Proceeds from Sale of Equity Securities, FV-NI							393,217	0
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal							$ 695,216	918,372
ONCO [Member] | Common Stock [Member]
Investment Owned, Balance, Shares (in shares) | shares			142,749				142,749
Proceeds from Sale of Equity Securities, FV-NI							$ 400,000
ONCO [Member] | Preferred Shares Converted to Common Shares [Member]
Conversion of Stock, Shares Converted (in shares) | shares			142,749
ONCO [Member] | Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio			40
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Asset Purchase Agreement [Member]
Disposal Group, Including Discontinued Operation, Consideration						$ 20,000,000
Proceeds from Sale of Productive Assets						6,000,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Asset Purchase Agreement [Member] | Promissory Notes Receivable, Due September 30, 2023 [Member]
Disposal Group, Including Discontinued Operation, Consideration						4,000,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Asset Purchase Agreement [Member] | Promissory Notes Receivable, Due April 19, 2024 [Member]
Disposal Group, Including Discontinued Operation, Consideration						5,000,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Asset Purchase Agreement [Member] | Promissory Notes Receivable, Due September 30, 2024 [Member]
Disposal Group, Including Discontinued Operation, Consideration						5,000,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Asset Purchase Agreement [Member] | Milestone Receivable [Member]
Disposal Group, Including Discontinued Operation, Consideration						80,000,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Asset Purchase Agreement, Amendment [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares					$ 1,000
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares					$ 0.5254
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal							$ 700,000	$ 900,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Asset Purchase Agreement, Amendment [Member] | ONCO [Member]
Preferred Stock, Convertible, Shares Issuable (in shares) | shares					5,709,935
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Asset Purchase Agreement, Amendment [Member] | ONCO [Member]
Preferred Stock, Convertible, Shares Issuable (in shares) | shares			142,749
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Asset Purchase Agreement, Amendment [Member] | Preferred Stock [Member] | ONCO [Member]
Stock Issued During Period, Shares, Purchase of Assets (in shares) | shares					3,000
Noncash or Part Noncash Divestiture, Amount of Consideration Received					$ 900,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Asset Purchase Agreement, Amendment [Member] | Promissory Notes Receivable, Due September 30, 2023 [Member]
Proceeds from Collection of Notes Receivable					1,000,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Asset Purchase Agreement, Amendment [Member] | Promissory Notes Receivable, Due September 30, 2023 [Member] | Note Receivable, Settlement Terms [Member]
Disposal Group, Including Discontinued Operation, Consideration					4,000,000
Proceeds from Collection of Notes Receivable					$ 1,000,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Asset Purchase Agreement, Amendment [Member] | Promissory Notes Receivable, Due April 19, 2024 [Member]
Proceeds from Collection of Notes Receivable				$ 50,000
Notes Receivable, Percentage of Revenues		25%		15%
Notes Receivable, Percentage of Net Proceeds	25%	20%		10%
Notes Receivable, Covenant, Minimum Net Capital Raised	$ 97,000
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Asset Purchase Agreement, Amendment [Member] | Promissory Notes Receivable, Due September 30, 2024 [Member]
Debt Instrument, Interest Rate, Stated Percentage									10%
ENTADFI [Member] | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | BWV Asset Purchase Agreement [Member] | Promissory Notes Receivable, Due September 30, 2024 [Member]
Disposal Group, Including Discontinued Operation, Consideration						$ 5,000,000			$ 3,500,000